IMI2 - Call 20 now open
The Innovative Medicines Initiative (IMI) has now launched its 20th Call for proposals under IMI2. The Call gives researchers from diverse sectors the opportunity to participate in ambitious public-private partnerships that will pave the way for the development of the medicines of the future.
Why apply?
- Obtain research funding
- Take part in scientifically excellent, patient-centric research
- Join unique consortia involving top teams from industry, academia, SMEs, regulators, and others
- Benefit from the expertise, databases, and infrastructures of consortium partners
- Boost the visibility and status of your organisation in Europe and globally and gain access to new markets
IMI2 – Call 20
IMI2 – Call 20 was launched on 21 January 2020 and is a standard, two-stage Call for proposals. It includes the following topics:
- Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in psoriatic arthritis
- Innovations to accelerate vaccine development and manufacture
- Academia and industry united innovation and treatment for tuberculosis (UNITE4TB)
- Tumour plasticity
- Proton versus photon therapy for oesophageal cancer – a trimodality strategy
- Handling of protein drug products and stability concerns
How to apply
The rules and details of how to apply can be found via the Call pages of the IMI website.
Follow IMI’s tips for applicants.
Get advice on finding project partners on this partner search page.
Sign up for the webinars here.
Deadline for short proposals: 21 April 2020
Source: Innovative Medicines Initiative
